Is Arbutus Biopharma Corp (ABUS) overvalued? · P/E 5.4, rev $6.2M
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
This page asks whether Arbutus Biopharma Corp (ABUS) looks expensive on cached numbers — not a short thesis.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ABUS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ABUS stock page for the full model, not this heading.
Not investment advice.